Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Digital Therapeutics Company to Present Evidence at 5th Neurological Disorders Summit


BRIDGEWATER, N.J., July 17, 2019 /PRNewswire/ -- JOGO Health Inc., a privately held digital therapeutics company focused on the development and commercialization of  treatments for neuromuscular (NM) conditions such as stroke, cerebral palsy and urinary incontinence today announced that it will present a poster on the evidence and performance of its lead investigational product JOGO, at the 5th Neurological Disorders Summit held at Four Points by Sheraton Los Angeles International Airport, Los Angeles, CA from July 18-19, 2019.

JOGO Health - Prescription Digital Therapeutics for Neuromuscular Conditions

The abstract, "Case study of utilization of digital therapeutics (JOGO) for post right MCA infarction" will be presented during the poster sessions on July 19, 2019 from 5-7 pm at  Salon D.

"I am particularly excited that we'll share a case study from JOGO - our non-invasive digital therapy built on the scientifically proven EMG biofeedback principles, that helped a patient with left hemiparesis post-right MCA infarction improve control of ankle dorsiflexors from 1+ to 3 (using MMT grades),  Barthel from 20/100 to 87/100 and a Berg Balance improvement of  93%"  said  Gary Krasilovsky,  PT, Ph.D., Chief Scientific Officer of JOGO Health Inc.

"We are proud to have developed one of the first evidence based digital therapeutics products to treat neuromuscular conditions, and a research philosophy that puts patients first and reduces treatment costs,"  he said.

There are 15 million new cases of a stroke worldwide every year.  In addition, 3 in 1,000 children are born with cerebral palsy and over 100 million women worldwide suffer from urinary incontinence.

About JOGO Health.

JOGO Health is a digital therapeutic company that developed JOGO,  a prescription digital therapeutics product to treat neuromuscular (NM) diseases such as stroke, spinal cord injury, cerebral palsy, bell's palsy, urinary and fecal incontinence and other NM disorders.

JOGO helps enhance rewiring of the CNS to improve voluntary control muscles that was lost  due to stroke and other neuro-muscular conditions. JOGO is composed of wearable wireless s/EMG sensors, and a patent protected Mobile App that provide treatment protocols and games that can be adapted for muscle relaxation, movement coordination, and neuro-muscular reeducation, all leveraging neuroplasticity.

Contact:
Sanjai Murali
[email protected]

SOURCE JOGO Health Inc.


These press releases may also interest you

at 22:30
Omnicom today announced the expansion of its Global Solutions Centers of Excellence with the opening of three new campus locations in Bengaluru, Chennai, and Gurugram. A fourth location will be opened in Hyderabad in October. This significant...

at 22:00
Guild of Guardians, the highly anticipated mobile RPG set to revolutionize the gaming industry, is proud to announce the upcoming launch of its epic Act 1 event, "Age of the Dread." To celebrate the first phase of the game's global release, Guild of...

at 21:53
Xiao-I Corporation ("Xiao-I" or the "Company"), a leading artificial intelligence company, is proud to announce a strategic partnership in April with a prominent Hong Kong insurance company. This collaboration aims to integrate Xiao-I's advanced AI...

at 21:09
Appvance and DMI have formed a strategic partnership to revolutionize the software quality landscape for enterprises in the public and private sectors. This partnership marks a commitment to accelerate digital transformation by harnessing the power...

at 21:00
OLED monitor display shipments significantly increased in 2023, following an upsurge of 415% year-over-year (YoY), according to Omdia's Monitor Display & OEM Market Tracker. This trend is set to continue with Omdia forecasting a 123% YoY increase in...

at 21:00
Renova Therapeutics, a biotechnology company developing gene therapy-based treatments for cardiovascular and metabolic diseases, announced today that it has focused its development and commercialization efforts for its RT-100 and RT-200 gene...



News published on and distributed by: